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Over the past 3 years many of South Africa’s largest and most 
prominent private-sector companies have announced and 
launched HIV/AIDS workplace treatment programmes.  These 
announcements have frequently been accompanied by much 
fanfare on the part of the companies and high praise in the 
media. However, evidence on the success these companies 
have had in enrolling employees in their care and treatment 
programmes and putting them onto antiretroviral therapy 
(ART) has been fragmented and anecdotal.  Considering the 
varied motivations for providing care and treatment – in some 
cases purely financial, in others at least partly humanitarian 
– it is important to understand the extent and success of these 
programmes, which have the potential to lessen the burden on 
the public sector of HIV/AIDS care and to reserve more ‘slots’ 
in the national AIDS treatment programme for those who 
cannot afford private care.
   The manner in which South African companies make 
HIV/AIDS care and treatment available to employees can be 
categorised into four models.1
   Model 1:  Employer provider.  The employer internally 
finances and delivers treatment and care for HIV-positive 
employees.  The company may use a ‘closed’ medical scheme 
(usually only available to employees of the company and their 
dependants), company clinic facilities, or a combination of the 
two.
   Model 2:  Medical aid scheme.  Employers subsidise medical 
aid scheme premiums for employees who choose to make 
the co-payment (medical aid schemes are similar to health 
insurance providers in the USA). Most medical schemes 
contract with a disease management programme (DMP) to 
handle the treatment and care of HIV-positive members.  
Medical aid scheme members must typically enrol separately 
in the DMP (i.e. enrolment is not automatic).
   Model 3: Independent disease management programme 
(DMP). A specialised HIV/AIDS disease management 
company is contracted by an employer to manage the costs and 
treatment of HIV-positive employees, independent of whatever 
medical aid scheme may be available. 
   Model 4: Clinic provider. An external treatment and care 
provider (clinic) is contracted by the employer to provide HIV-
related services either at the workplace or at an outside clinic.
   Each of these models of care and treatment involves some 
level of financial cost to the employer.  How effective the 
different models of care and treatment have been in enrolling 
HIV-positive members and providing high-quality care and 
treatment has rarely been communicated by providers or 
purchasers of the services.  The most revealing information has 
come from Anglo American, which has developed an extensive 
programme following the ‘employer provider’ approach.  After 
more than 2½ years of operation, about 22% of those believed 
to be HIV-positive have enrolled in the programme and just 
under 3 000 have started on ART.  Results in some divisions 
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of the company have been extremely encouraging – nearly 
100% uptake of both DMP and ART in one mine, for example 
– but patient attrition has also been high.  Nearly 30% of those 
started on ART are no longer being treated. However, despite 
low overall enrolment in the DMP and high attrition from ART, 
it is likely that Anglo American has one of the most successful 
private-sector programmes in the country.2,3 
   In the second half of 2004 we conducted a brief telephone 
survey of the largest private-sector employers in South Africa 
to determine what proportion of employees have access to 
HIV/AIDS care and treatment, including ART; how many 
employees are enrolled in DMPs; how many are receiving ART; 
and which approach to the financing and delivery of care is 
proving most successful at reaching eligible employees.  We 
asked interviewees about the results of any estimates done 
for or by the company with regard to HIV prevalence among 
employees.
   Two recent developments in South Africa are important in 
understanding the results that follow.  First, in 2004 South 
Africa began providing ART through public hospitals and 
clinics.  As of early 2005, some 30 000 patients were receiving 
care at public ‘ARV rollout’ sites.  Although universal access to 
ART is the long-term goal of the national programme, scaling 
up services will take many years, and currently only about 6% 
of medically eligible patients are receiving ART.4  Although 
many employers will rely on the public sector to take care of 
HIV-positive workers, it is not safe to assume that employees 
will have ready access to treatment at public clinics for many 
years to come.  The second relevant development occurred 
in 2005 when ART was added to the ‘prescribed minimum 
benefits’ that medical aid schemes are required to provide.  
Employees who belong to medical aid schemes can therefore 
be assumed to have access to ART.  
Methods
All private and parastatal companies with 6 000 or more 
permanent employees were included in our population.  
Employment figures were provided by Matrix Marketing, 
a private-sector database consulting company.  Structured 
interviews were conducted by telephone between September 
and November 2004.  At each company we interviewed the 
HIV/AIDS programme manager, human resources manager, or 
another individual with knowledge of the current status of the 
programme.  
   Interviews included questions about the size of the 
company’s labour force in South Africa, estimated prevalence 
of HIV in the workforce, commencement date of the HIV/
AIDS disease management or treatment programme, number 
of employees enrolled in the programme, and number of 
employees currently receiving ART.  Interviewees were also 
asked about the manner in which HIV disease management 
services and ART were being delivered and financed.  
Results
Access to AIDS care and treatment
Of the 64 companies in our study population, 52 participated 
in the study.  Ten companies were unresponsive to repeated 
telephone and e-mail requests for information and 2 companies 
refused to participate.  Characteristics of the participating 
companies are presented in Table I.  Because of the workforce 
size requirement for the study population (at least 6 000 
employees), some of the South African firms whose HIV/AIDS 
programmes have received the most publicity, such as Daimler-
Chrysler South Africa, are not included in the sample.5 
   All of the surveyed companies offered to subsidise medical 
aid membership for some or all of their employees, typically 
paying 50% of the premium for employees and dependants.  
For medical aid scheme members, ART is a standard benefit. 
However, only a minority of all employees actually belong 
to a medical aid.  Membership is optional and typically 
concentrated among managers and supervisors, who also 
are least likely to be HIV-positive.  Few unskilled workers 
opt to join, presumably because the 50% co-payment is very 
high for a low-wage worker. Since all of the companies have 
at least some employees on medical aid, none of them can 
be said to provide no access to ART. However, since medical 
aid membership is typically very low among the majority 
of the workforce in the skilled and unskilled job bands, we 
considered a company to have an AIDS treatment programme 
only if all of its employees had access to ART, regardless of 
which model or models were used. 
   Roughly half of the companies surveyed (N = 25) made ART 
available to all permanent employees.  Coverage of HIV/AIDS 
treatment access varied by industry, as shown in Table II.  All 
financial services companies and three-quarters of mining 
companies made ART available to all employees, but only 21% 
Table I.  Characteristics of surveyed companies
 No. (%) of    
 surveyed  Total No. of Average No.
Industry companies employees of employees
Retail   14 (27) 157 100  11 221
Mining   12 (23) 313 915 26 160
Manufacturing     7 (13)   64 200   9 171
Financial services     6 (12) 133 434 22 239
Community, social 
and personal 
services (CSPS)      4 (8)   78 400 19 600
Transport, storage 
and communication 
(TSC)      4 (8) 145 000 36 250
Construction      3 (6)   31 500 10 500
Agriculture      2 (4)   18 200   9 100
   Total 52 (100) 941 749  18 111
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of retail firms and none of the construction or community, 
social and personal services (CSPS) companies did so.  
   On average, 63% of permanent employees of surveyed firms 
had access to HIV/AIDS care and treatment financed by their 
employer.  This figure is driven largely by widespread access in 
the mining and financial industries. 
HIV prevalence
In order to analyse the enrolment rates of HIV-positive 
employees in HIV DMPs and on ART, we asked if the 
respondent’s company had estimated the prevalence of HIV 
among its employees.  Thirty-four of the surveyed companies 
had made such estimates, and 27 were willing to disclose the 
results to our interviewers.  The average prevalence of HIV 
infection at the 27 reporting companies was 15.2%.  In the 
mining sector, 9 of the 12 participating companies provided 
prevalence estimates, and the average prevalence was 18.3%.  
For retail/wholesale and manufacturing, 5 companies in each 
sector provided estimates, and the average infection levels 
were 11.7% and 10.7%, respectively.  Estimates of prevalence 
were provided by only a few companies in the financial, 
telecommunications, agriculture and CSPS sectors.
Utilisation of ART benefits
Table III provides results on treatment programme monitoring, 
enrolment, and ART uptake.  Monitoring by companies 
of utilisation of their AIDS treatment benefit varied.  
Approximately half the companies in our survey (N = 25), 
with a combined workforce of roughly 600 000, could tell us 
the number of employees enrolled in the HIV DMP and/or the 
number receiving ART.  At these companies, 26 010 employees, 
or 4.4% of the total, were enrolled in HIV/AIDS DMPs at the 
time of the survey. Approximately 3 908 employees, or 0.7% of 
the total, were currently receiving ART.  
Treatment programme models
We distributed the surveyed companies among the three 
models of treatment provision based on the characteristics of 
their treatment programmes.  Looking only at those companies 
that made treatment available to all employees, 10 had adopted 
the independent DMP model (model 3), 9 the employer 
provider model (model 1), and 6 the medical scheme model 
(model 2).  No companies surveyed purchased services from 
a clinic provider (model 4).  As previously mentioned, all the 
remaining companies (N = 27) had at least some employees 
Table III.  Utilisation of treatment and care, end 2004
   No. of  % of  No. of  % of  all   
 No. of companies No. of  employees employees in  employees employees
Industry reporting uptake employees in HIV DMP HIV DMP on ART on ART
Retail    3   44 900        70 0.2      52 0.1
Mining    9 275 300 24 066 8.7 2 954 1.1
Manufacturing    4   36 700           Insufficient data* NA    518 1.4
Financial services    4  112 500     910† 0.8   330† 0.3
CSPS    0       NA     NA NA   NA NA
TSC    3 119 000      824 0.7        6 0.0
Construction    0       NA     NA NA   NA NA
Agriculture    2     8 475      140 1.7      48 0.6
   Total  25 596 875 26 010 4.4 3 908 0.7
*Two of the manufacturing firms did not provide information on DMPs.  One did not have an HIV DMP and the other did not know how many employees were enrolled.
†Utilisation figures for the four financial companies include dependants.
CSPS = community, social and personal services; TSC = transport, storage and communication; DMP = disease management programme.
Table II. Number and proportion of employees with access to ART, by industry
   No. making ART % making ART  
 No. of companies available to all  available to all  No. of employees %  of employees
Industry surveyed employees employees with access* with access
Retail 14    3   21   83 939   37
Mining 12   8   75 273 919   90
Manufacturing   7   5   71   55 600   80
Financial services   6   6 100 133 434 100
CSPS   4   0     0     8 760   13
TSC   4   2   50 130 660   74
Construction   3   0     0     8 080   51
Agriculture†   2   1   50     2 875   59
   Total 52 25   48 697 267   63
*From all companies, including those for which only some employees have access.
†Information from one of the agriculture companies was only available for one unit.
CSPS = community, social and personal services; TSC = transport, storage and communication.
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with access to treatment through their medical aid scheme, but 
the proportion of employees covered in these firms was low, 
averaging 32%.
   The breakdown of model choice by sector is shown in  
Table IV.  Most of the companies with an internal programme 
(model 1) were in the mining sector, while most of those in 
which all employees were covered by medical aid (model 2) 
were in the financial services sector.  
   There are significant differences in monitoring, access to, and 
utilisation of HIV/AIDS treatment and care benefits between 
companies using different models, as shown in Table V.  All 
companies offering HIV/AIDS treatment and care internally 
(employer provider) or through an independent DMP had 
made estimates of HIV prevalence among employees and knew 
enrolment rates into DMPs and onto ART.  Of the 33 companies 
relying on medical schemes for HIV/AIDS treatment and 
Table V. Coverage of HIV/AIDS treatment and care benefits by model, end 2004
   Model 2:*   No programme: 
  Medical scheme  Model 3: Partial coverage 
 Model 1: DMP (all employees Independent  through medical  
Variable Employer provider covered) DMP scheme Total
No. and proportion (%)     
of companies reporting 
HIV prevalence, DMP 
enrolment, and ART rates  9 (100)    5 (50)  6 (60)  3 (13)  23 (44)
No. of employees at 
companies reporting HIV 
prevalence, DMP        
enrolment, and ART rates 273 424 249 545 97 474 30 800 651 243
Estimated HIV prevalence (%)      19.4        4.9        9.8     14.3      15.2 
     (weighted)
Inferred number of HIV-
positive employees   53 044   12 228   9 552   4 404   98 989
No. of HIV-positive 
employees enrolled 
in DMP   23 332     1 690   1 136      376   26 534
Proportion (%) of 
estimated HIV-positive 
employees enrolled in DMP       44.0      13.8       11.9       8.5       26.8
No. of HIV-positive 
employees receiving ART     2 719       330      650       73     3 772
Proportion (%) of estimated
HIV-positive employees 
receiving ART         5.1        2.7       6.8      1.7        3.8
*Utilisation figures for four of the model 2 companies include dependants.
DMP = disease management programme.
Table IV.  HIV/AIDS treatment model utilised by surveyed companies   
   Model 2:  No programme: 
   Medical scheme   Partial coverage 
 No. of companies  Model 1: (all employees  Model 3: through medical  
Industry surveyed Employer provider covered) Independent DMP scheme  
Retail 14 1 1   1 11  
Mining 12 7 0   1   4
Manufacturing   7 1 0   4   2
Financial services   6 0 4   2   0
CSPS   4 0 0   0   4
TSC   4 0 1   1   2
Construction   3 0 0   0   3
Agriculture   2 0 0   1   1
   Total 52 9 6 10 27
CSPS = community, social and personal services; TSC = transport, storage and communication; DMP = disease management programme.
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care, 12 knew utilisation rates. However, 4 of these companies 
refused to reveal the information to the study team.
   To estimate uptake ratios for DMPs and ART, we required an 
estimate of HIV prevalence, the number of employees enrolled 
in the DMP, and the number currently on ART.  We obtained all 
three variables from 23 companies.  Overall, 27% of suspected 
HIV-positive employees were enrolled in DMPs and 3.8% were 
receiving ART.  Companies making treatment services available 
internally (model 1) reported that 44% of HIV-positive 
employees were enrolled in DMPs, more than three times 
higher than the independent DMP or medical scheme models.  
This may reflect the greater success of model 1 companies in 
promoting HIV testing among employees.  Many companies 
with internal programmes also have longstanding ‘HIV 
wellness programmes’ that predate the introduction of ART by 
several years. In contrast, companies using independent DMPs 
reported the highest rate of ART uptake – 6.8% versus 4.2% 
and 2.4% for companies using the employer provider and the 
medical scheme model, respectively.
Discussion
To date most of the information available on HIV/AIDS 
treatment and care programmes at very large companies in 
South Africa has come from a small number of high-profile 
companies communicating the success of their efforts.  Few 
details have been released on the extent of access to and 
utilisation of HIV/AIDS benefits.  The findings reported here 
serve as an indication to government and funding agencies of 
the contribution of large private-sector employers to national 
treatment goals, and as a signal to individual companies about 
the relative achievements of their programmes.  
   We found a high average level of access to HIV/AIDS 
care and treatment, including ART, for the entire employee 
population of the surveyed firms. However, this result was 
largely driven by the extensive access to benefits at the large 
mining houses and financial services firms.  Many companies 
in other sectors continue to rely solely on medical aid schemes 
for which the majority of employees cannot (or choose not 
to) afford the premiums.  Although all employees at these 
companies do have access to medical aid coverage, wages 
are not high enough to make it a viable option.  We therefore 
regarded employees not covered by medical aid at these 
companies as not having access to AIDS treatment.  
   Based on estimates of HIV prevalence and service utilisation 
supplied by the individual companies, we found the overall 
enrolment levels of HIV-positive employees into companies’ 
treatment programmes to be low.  We estimate that fewer 
than one-third of those with HIV are aware of their own 
status and enrolled in an HIV DMP, while approximately 4% 
of HIV-positive employees – 0.6% overall – are currently on 
ART.  Assuming that an average of 15% of employees are 
HIV-positive, as indicated in Table V, and at least 10% of HIV-
positive South Africans are medically eligible for ART, far 
fewer employees are accessing treatment than currently need 
the therapy.6 If we extrapolate the reported uptake rates to all 
52 large companies, the result is an estimated 8 000 patients 
on ART.  While this clearly underestimates the total number 
of private-sector employees on employer-sponsored ART, as it 
excludes the very large employers who refused to participate 
and the many large and medium-sized companies in which 
some employees are on ART, the true number is certainly far 
smaller than the estimated 30 000 patients being treated with 
antiretrovirals in the public sector at the time of the survey.7
   Programme monitoring, access to care and treatment, and 
uptake of benefits seem to be related to the model of service 
delivery and financing in use.  Few companies relying on 
medical aid schemes to deliver treatment and care (model 2), 
for example, were able to report uptake figures.  The reason 
given by many companies was that the medical scheme 
administrators do not or will not report utilisation rates, even 
though the companies typically subsidise 50% of the medical 
aid scheme premiums.  Companies using model 1 (employer 
DMP) or model 3 (independent DMP) were more likely to 
make ART available to all their employees and reported higher 
uptake of services than companies relying exclusively on 
medical schemes.  
   We did not explore the reasons for the observed low uptake 
of benefits and differences in uptake rates among companies.  
The greater uptake reported by companies with employer or 
independent DMPs probably reflects better uptake of voluntary 
counselling and testing (VCT), which in turn results from 
active VCT campaigns by the employers and their DMPs.  
We assume that overall low uptake of treatment services is 
caused by stigma surrounding HIV/AIDS, lack of trust among 
employees that their employer will not learn their status, 
and the newness of many programmes. The commitment of 
companies and managers implementing the programmes, 
approaches to recruiting employees into them, and the quality 
of the programmes themselves may also be important.
   Each of the models for employer-sponsored HIV/AIDS 
disease management has limitations.  In-house programmes 
(employer DMPs) may not be feasible if health care is not 
already provided to all employees.  Very few companies 
have the resources or expertise necessary to run an in-house 
programme.  There are only a handful of independent DMPs 
operating in South Africa, and quality seems to vary widely.  
Since most companies already offer medical aid coverage, 
making it affordable and compulsory for all employees may 
be the simplest way to extend access to ART.  As noted above, 
however, medical aid schemes have been the least successful in 
promoting uptake of services.  
   One innovative approach to extending access to ART through 
a public-private partnership was reported by an agricultural 
company and a company in the CSPS sector.  These companies 
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provide some of the support services necessary for ART, such 
as screening and counselling, but rely on government facilities 
for physicians, laboratory tests, and antiretroviral medications.  
While this model is dependent on having a nearby public 
treatment facility, it may prove more feasible and affordable for 
some employers than the existing models.
   The study had several limitations.  First, 12 of the 64 
companies in our study population refused to participate.  
The companies that did not participate are distributed across 
most industrial sectors (retail, manufacturing, construction, 
agriculture, energy, and CSPS).  From information reported 
by the media, at least five of the non-participating companies 
have active treatment and care programmes in place.  A 
second limitation is the source of the data – uptake figures 
were reported by company representatives and could not be 
verified.  Finally, in the case of five companies, information 
was provided for only one operating unit. 
   We conclude that publicity by large employers about their 
treatment programmes should be interpreted cautiously. The 
notion that business will play a significant role in meeting 
national and international treatment goals is uncertain.  The 
extent of the current private-sector contribution to national 
treatment goals is less than the limited media coverage might 
lead us to believe.  At this point it appears that even some 
of South Africa’s largest employers will wait for the national 
public treatment programme to assume responsibility for 
employees sick with AIDS.  However, the study team noted 
a good deal of confusion regarding government provision of 
ART, options for making ART available to employees, and 
other policy questions.  Clarifying these issues for employers 
may encourage more, and more effective, employer-sponsored 
programmes.
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   A brief summary of the findings presented here was published in 
a letter to the editor of the Lancet.  Full citation:  Connelly P, Rosen 
S. Provision of antiretroviral therapy by the private sector (letter). 
Lancet 2005; 365: 1925-1926.
References
1.  Connelly P, Rosen S. Can small and medium enterprises in South Africa provide HIV/AIDS 
services to their employees? A market analysis. CIHD Project Report, March 2004.   http://
www.bu.edu/dbin/sph/research_centers/cih_impact_hiv.php (last accessed 25 May 2005).
2.  Brink B.  An interim appraisal of the Anglo American AIDS treatment programme.  Plenary 
presentation at the 2nd South African AIDS Conference, Durban, South Africa, 10 June 2005.
3.  Kahn T.  Anglo workers slow to accept offer of free AIDS drugs. Business Day, 17 February 
2005. www.businessday.co.za/Articles/TarkArticle.aspx?ID=1377835 (last accessed 25 May 
2005).
4.  Rosen S, Sanne I, Collier A, Simon J.  Rationing antiretroviral therapy for HIV/AIDS in 
Africa:  choices and consequences.  PLoS Medicine (in press).
5.  Planting S. Champions of the AIDS cause. Financial Mail, 5 September 2003. http://free.
financialmail.co.za/innovations/0905/iinn.htm (last accessed 6 June 2005). 
6.  Dorrington RE, Bradshaw D, Johnson L, Budlender D.  The Demographic Impact of HIV/AIDS 
in South Africa. National Indicators for 2004. Cape Town: Centre for Actuarial Research, South 
African Medical Research Council and Actuarial Society of South Africa, 2004. 
7.  Irin.  South Africa:  capacity shortfalls undermine roll-out.  Irin PlusNews 3 March 2005.  
http://www.irinnews.org/pnprint.asp? reportid=4546 (last accessed 4 March 2005).
Visit our  
Professional Advertising  
section at the back of this SAMJ 
Journal
pg 128-133.indd   133 1/18/06   10:40:31 AM
